ArticleEuropean journal of pediatrics2013
Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab.
Article in European journal of pediatrics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Pediatric idiopathic steroid-sensitive nephrotic syndrome: diagnosis and therapy -short version of the updated German best practice guideline (S2e) - AWMF register no. 166-001, 6/2020.Pediatric nephrology (Berlin, Germany) · 2021Guideline
- Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.Pediatric nephrology (Berlin, Germany) · 2017Trial
- Response predictors and long-term outcomes of preprandial single-daily cyclosporine in children with steroid-dependent nephrotic syndrome.Journal of nephrology · 2025Article
- Long-term outcome of mycophenolate mofetil after a single dose of rituximab in childhood-onset refractory idiopathic nephrotic syndrome.Clinical and experimental nephrology · 2025Article
- Steroid-sensitive nephrotic syndrome in children: Korean Society of Pediatric Nephrology clinical practice recommendations.Childhood kidney diseases · 2025Article
- Clinical practice guidelines for rituximab treatment in children with steroid-sensitive nephrotic syndrome.World journal of pediatrics : WJP · 2025Review
- Steroid-sensitive nephrotic syndrome in children: Korean Society of Pediatric Nephrology clinical practice recommendations.Kidney research and clinical practice · 2025Article
- Clinical applicability of 2023 International Pediatric Nephrology Association recommended limited therapeutic drug monitoring formulae to assess mycophenolic acid exposure.Pediatric nephrology (Berlin, Germany) · 2025Article
- A digest of the clinical practice guideline for pediatric idiopathic nephrotic syndrome 2020 updated: medical therapy.Clinical and experimental nephrology · 2025Review
- Efficacy and safety of long-term repeated use of rituximab in pediatric patients with nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2024Article
- Predictive factors of long-term disease remission after rituximab administration in patients with childhood-onset complicated steroid-dependent nephrotic syndrome: a single-center retrospective study.Clinical and experimental nephrology · 2023Article
- CD4 + and CD8 + T-lymphocyte number as predictive marker of relapse after rituximab treatment in childhood-onset refractory nephrotic syndrome.Clinical and experimental nephrology · 2023Article
- Recent Advances in Therapeutic Drug Monitoring of Voriconazole, Mycophenolic Acid, and Vancomycin: A Literature Review of Pediatric Studies.Pharmaceutics · 2021Review
- Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective studyTurkish journal of medical sciences · 2021Article
- Rituximab in children with steroid sensitive nephrotic syndrome: in quest of the optimal regimen.Pediatric nephrology (Berlin, Germany) · 2021Review
- Prophylactic rituximab administration in children with complicated nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2021Article
- Unfavorable impact of anti-rituximab antibodies on clinical outcomes in children with complicated steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2020Article
- Podocytopathies.Nature reviews. Disease primers · 2020Review
- Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study.Pediatric nephrology (Berlin, Germany) · 2019Observational
- Rituximab for Children With Difficult-to-Treat Nephrotic Syndrome: Its Effects on Disease Progression and Growth.Frontiers in pediatrics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledThe efficacy of rituximab (RTX) as the sole therapy for preventing relapses of nephrotic syndrome (NS) is transient in most patients; therefore, the optimal therapy required for maintaining a successful response to a biological agent remains a challenge. We conducted a prospective study to compare the efficacy of cyclosporine (CsA) with that of mycophenolate mofetil (MMF) as maintenance therapy after a single infusion of RTX. Of 29 patients with persistent steroid-dependent NS despite the use of CsA and/or MMF, 13 without chronic nephrotoxicity continued CsA therapy, maintaining a 2-h post-dose CsA level of 400-500 ng/ml (CsA group). The remaining 16 were treated with MMF, maintaining a pre-dose level of 2-5 μg/ml of mycophenolic acid (MMF group). The median duration of CsA and MMF treatment was 18 and 19 months, respectively. Despite the mean number of relapses before RTX treatment being significantly lower in the MMF group than in the CsA group (2.3/year vs. 4.6/year, p < 0.01), treatment failure occurred more frequently in the MMF group (7/16) than in the CsA group (2/13). The rate of sustained remission was also significantly higher in the CsA group than in the MMF group (p < 0.05).
conclusionIn patients with severe steroid-dependent NS, CsA appears to be more effective than MMF for maintaining remission after a single infusion of RTX.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.